BIOMAT Database Logo BIOMAT Database Logo

A modular approach to HIV-1 proteinase inhibitor design. 1996

T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic. uhlikova@prfdec.natur.cuni.cz

HIV-1 proteinase represents a promising target for antiviral chemotherapy. We have designed, synthesized, and tested modular inhibitors combining an active-site inhibitor tethered to a structure targeted to the dimerization domain of the enzyme. At pH 5 the parent active site inhibitor, the equimolar mixture of active site and dimerization inhibitors, and the best compound from our series of modular inhibitors show the same inhibition activity. At neutral pH, however, the combination of the dimerization and active-site inhibitors shows a synergistic effect. Moreover, the modular inhibitor has an IC50 value 5x lower than the parent active site inhibitor and 2x lower than the equimolar mixture of the two parent inhibitors. The Lineweaver-Burk plot for modular inhibitors corresponds to a pattern for mixed type inhibition.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach.
February 2000, Journal of computer-aided molecular design,
T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
A modular approach to case report design.
January 1976, Drug information journal,
T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.
June 1995, AIDS research and human retroviruses,
T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
Designing repeat proteins: a modular approach to protein design.
August 2017, Current opinion in structural biology,
T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
A modular design approach to polymer-coated ZnO nanocrystals.
January 2023, iScience,
T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
Saquinavir: an HIV proteinase inhibitor.
January 1996, Advances in experimental medicine and biology,
T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
Structure-based design of a novel peptide inhibitor of HIV-1 integrase: a computer modeling approach.
August 2002, Journal of biomolecular structure & dynamics,
T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
HIV therapy advances. Update on a proteinase inhibitor.
September 1994, AIDS (London, England),
T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
A new approach to the general detection and measurement of proteinase and proteinase inhibitor activities.
November 1982, Biochimica et biophysica acta,
T Uhlíková, and J Konvalinka, and I Pichová, and M Soucek, and H G Kräusslich, and J Vondrásek
Structure-based inhibitor design targeting HIV-1 integrase.
September 2002, Current drug targets. Infectious disorders,
Copied contents to your clipboard!